The effect of neonatal treatment with capsaicin on focal arteriolar insudation.

There is evidence that peptide neurotransmitters (e.g., substance P, neurokinin A, vasoactive intestinal peptide, calcitonin gene-related peptide) from sensory nerves play a part in vasoregulation. We examined the effect of neonatal treatment with capsaicin, a procedure that causes permanent impairment of primary sensory neurons, on a recently described arteriolar response to inflammation, focal arteriolar insudation (FAI). FAI occurs at a distance from the site of injury, in arterioles supplying that area, and is first observed 6 hr after onset of inflammation and maximally at 24 hr; the affected arterioles show dilation, with increased endothelial permeability and occasional smooth muscle cell damage. In our model, inflammation is induced by implanting a sterile plastic disk in the connective tissue superficial to the rat cremaster muscle. When carbon black is injected intravenously 24 hr later, FAI in the cremaster arterioles can be detected on light microscopy as areas of carbon extravasation; and the length of affected segments is morphometrically measured. The capsaicin-pretreated group showed a marked decrease in FAI compared to the controls. Mean FAI in the capsaicin group (12 animals) was 1.8 +/- 2.4 (SD) mm/cremaster compared to 5.6 +/- 5.1 for the control group (12 animals). P less than 0.003. These results provide evidence that this arteriolar response to inflammation is modulated in part by capsaicin-sensitive neurons.

Studies on the role of catecholamines in the regulation of the developmental pattern of hypothalamic aromatase.

Experiments were conducted to study the regulation of the developmental pattern of aromatase in the forebrain of the perinatal rat. Two experimental designs were used: aromatase measured in primary cultures of fetal hypothalamic cells and in cell-free preparations of forebrain tissue excised at varying ages. In cultured cells, aromatase decreased logarithmically at a slow rate (t1/2 = 7.8 days). Norepinephrine caused a pronounced dose (4 x 10(-6) M) and time-dependent (2-6 days) drop in aromatase without affecting the levels of 5 alpha-reductase or substance P. In isolated tissue, aromatase activity was compared with the concentrations of norepinephrine and dopamine in the forebrain of males vs females at different perinatal ages and in discrete forebrain areas at postnatal day 4. In no case was a sex difference in catecholamines seen. An overall developmental decline in aromatase was associated with developmental increases in catecholamine levels. Acute treatment with the beta-agonist, isoproterenol, had no effect on brain aromatase activity.

Localization of aromatase and 5 alpha-reductase to neuronal and non-neuronal cells in the fetal rat hypothalamus.

Experiments were designed to identify the neural cell type(s) responsible for the aromatization and 5 alpha-reduction of androgens in the rat hypothalamus. Primary cultures of fetal rat hypothalamic cells, which had enhanced neuronal morphology, were treated at various times after plating with kainic acid (KA), a neurotoxic agent which selectively destroys neuronal cells. Neuronal morphology was disrupted in a time (0-6 days)- and dose (10(-4)-10(-2) M)-dependent fashion after KA treatment, with no apparent change in the appearance of the flattened, underlying non-neuronal cells. KA treatment for 4 days decreased aromatization by 94% in a dose-dependent fashion (10(-4)-10(-2) M KA), while 5 alpha-reduction declined by no more than 25%. A 6-day time course with 10(-3) M KA showed a dramatic decline in aromatization and no alteration in 5 alpha-reduction. In control experiments, substance P, a neuronal peptide, declined after KA treatment while the activity of glutamine synthetase, a glial enzyme, did not change. We conclude from these results that aromatase is localized primarily to neuronal cells in the hypothalamus while 5 alpha-reductase is confined primarily to non-neuronal cells.

Immunoreactive neurotensin levels in pancreas: elevation in diabetic rats and mice.

Neurotensin levels in pancreas, but not other tissues, were increased in diabetic animals. The concentration of pancreatic immunoreactiveneurotensin was 138% higher in streptozotocin-diabetic rats, and 68% higher in genetically diabetic (db/db) mice as compared to their respective control animals. Daily administration of insulin (10-15 IU/kg) to diabetic rats completely reversed this effect, and pancreatic neurotensin levels in these animals returned to control values. These findings suggest that elevated levels of pancreatic neurotensin may contribute to some of the metabolic and hormonal disturbances occurring in diabetes.

Release of immunoreactive somatostatin from hypothalamic cells in culture: inhibition by gamma-aminobutyric acid.

Primary cultures of dispersed hypothalamic cells were prepared from embryonic rats to study the release of immunoreactive somatostatin. The immunoreactive somatostatin content of these cultures increased during the first 2 weeks after plating and was readily measurable for several weeks thereafter; this material was characterized by gel permeation and reverse-phase chromatography. Depolarization of the cells with 60 mM K+ or with veratridine resulted in a calcium-dependent release of immunoreactive somatostatin which cochromatographed with synthetic somatostatin on reverse-phase chromatography. Tetrodotoxin blocked the veratridine-evoked release. However, even in the absence of exogenous stimuli, immunoreactive somatostatin was released by the cells into the medium. More than 70% of this tonic release was found to be calcium dependent and to be inhibited by tetrodotoxin, indicating that spontaneous electrical activity in the cultures leads to a release of immunoreactive somatostatin. gamma-Aminobutyric acid inhibited the tonic release of immunoreactive somatostatin and this was reversed by bicuculline. These findings support the hypothesis that gamma-aminobutyric acid inhibits somatostatin release in vivo.

Primary cultures of dispersed hypothalamic cells from fetal rats: morphology, electrical activity, and peptide content.

Cultures prepared from dispersed fetal hypothalamic tissue have cells which can be identified as neurons by their morphology and electrical activity. The elongation of neuritic processes in these cultures is increased by treatment with 1-beta-D arabinofuranosylcytosine (ara-C). Hypothalamic cultures have measurable quantities of immunoreactive substance P and neurotensin, and the neurons can accumulate (3H)GABA.

Neurotensin neurons in the rat hypothalamus: an immunocytochemical study.

Neurotensin was localized in the hypothalamic tissues of adult Sprague-Dawley rats by immunoperoxidase techniques. Visualization of perikarya was greatly enhanced by intraventricular administration of colchicine. Many perikarya containing neurotensin-like immunoreactivity were seen in the medial preoptic area, the periventricular hypothalamus, the parvocellular portion of the paraventricular nucleus, the arcuate nucleus, and the lateral hypothalamus in the perifornical area. There were moderate numbers of cell bodies in the ventral portion of the anterior hypothalamus, the dorsomedial nucleus, and the posterior hypothalamus. No positive cells were seen in the suprachiasmatic, ventromedial, or mammillary nuclei. Reactive fibers were generally distributed in the same regions as cell bodies. Additional dense collections were seen in the lateral part of the zona externa of the median eminence, the pituitary stalk, the posterior mammillary nucleus, and the most lateral portions of the hypothalamus at the medial edge of the crura cerbri. There were smaller numbers of fibers found in the pre-mammillary and posterior hypothalamic nuclei and the posterior pituitary gland. These results indicate that the neurotensin system in the hypothalamus is very extensive and complex, as it is in many other brain regions. Neurons and fibers are found in many hypothalamic areas, including projections to the hypophysial portal system in the median eminence, suggesting that neurotensin may affect neuroendocrine mechanisms at several levels, including the anterior pituitary gland.

Isolation of human intestinal neurotensin.

The biologically active peptide neurotensin (NT) has been isolated from fresh postmortem human small intestine and its identity with bovine hypothalamic and intestinal neurotensin has been established. Purification was achieved by gel filtration and two ion exchange chromatography steps; material was detected by radioimmunoassay (RIA). A substance was obtained that had integral molar ratios of amino acids and eluted in a single peak during reverse-phase high pressure liquid chromatography (HPLC). This material had an amino acid composition and COOH-terminal sequence identical with those of bovine NT. Human and bovine neurotensin gave rise to the same fragments when treated with papain; they were indistinguishable in RIAs using three different region-specific antisera and in their hypotensive effect on anesthetized rats. Using mucosal scrapings obtained immediately post-mortem from four subjects, the concentration of immunoreactive neurotensin was found to increase from duodenum to distal ileum, in agreement with results obtained in other mammalian species.

The amino acid sequence of bovine hypothalamic substance P. Identity to substance P from colliculi and small intestine.

Bovine substance P has been isolated in pure form from hypothalamic fragments and its complete amino acid sequence determined by studies performed on the intact peptide and on its isolated papain-generated fragments. Direct evidence for the positioning of each residue was obtained, amide assignments were unequivocally established, and the COOH-terminal residue was isolated and identified as Met-NH2. The results of total enzymic digestion performed on each of the peptides obtained argue against the presence of any non-amino acid constituents in the molecule. The amino acid sequence obtained is identical with that previously reported for material isolated form bovine colliculi and from equine small intestine.

The amino acid sequence of radioimmunoassayable neurotensin from bovine intestine.

The amino acid sequence of radioimmunoassayable neurotensin, isolated from bovine small intestinal extracts, has been shown to be the same as that of the peptide originally isolated from bovine hypothalamic extracts. This was accomplished by sequence studies on the intact peptide as well as on its chymotryptic and papain-generated fragments. Thus, neurotensin joins the group of biologically active peptides shown to be present in the same molecular form in both brain and intestine.

The aromatization of androgens by primary monolayer cultures of fetal rat hypothalamus.

Aromatization of [3H]androstenedione and [3H]19-hydroxyandrostenedione to [3H]estrone has been demonstrated to occur in one to two week old primary monolayer cultures of fetal rat hypothalamus. Three times more estrone is produced from 19-hydroxyandrostenedione than from androstenedione in four day incubations. Cultures treated with cytosine arabinoside have 50% less cellular protein and produce three times more estrone from either substrate than untreated cultures. Time course experiments using cultures treated with cytosine arabinoside indicate that aromatization of 19-hydroxyandrostenedione is linear for three days and can be quantitatively measured within the first two to eight hours of incubation.

Hyperglycemic effect of neurotensin, a hypothalamic peptide.

A hypotensive, gut-contracting peptide neurotensin (NT), recently isolated from bovine hypothalami, has been found to produce hyperglycemia within minutes after iv injection into anesthetized rats. The dose-response relationship (deltaglucose, 15 min after injection) was linear over the range 30-200 pmol/100 g BW. NT did not alter the disappearance rate of [14C]glucose from plasma during the development of the hyperglycemia. However, the peptide caused a fall in liver glycogen (52 +/- 6.5 to 41 +/- 3.3 mg/g) and a 7-fold increase in the activity of the 5'-AMP independent form of liver glycogen phosphorylase. Activation of liver glycogen phosphorylase did not occur in vitro under conditions found suitable for demonstrating the effectiveness of glucagon, suggesting the possible involvement of an intermediary substanc(s) in vivo. Acute adrenalectomy did not prevent the response. Hypophysectomized rats (4 days post-operative) were less sensitive to NT, perhaps as a consequence of their diminished liver glycogen levels (normal, 52 +/- 6.5 mg/g; hypophysectomized, 23 +/- 1.8 mg/g); however, the presence of the pituitary was not essential for this response. NT was also effective in rats with hereditary diabetes insipidus (Brattleboro strain). At the time intervals sampled, radioimmunoassayable plasma levels of growth hormone, glucagon, and insulin were not significantly changed after injection of NT into normal rats. Pretreatment of rats with reserpine (7 mg/kg), morphine sulfate (10 mg/kg), propranolol (5mg/kg), or phenoxybenzamine (10 mg/kg) did not prevent the response. These findings characterize the action of NT on liver glycogen metabolism and blood glucose levels, but a physiological role for NT in this regard remains to be demonstrated.

Regional distribution of substance P in the brain of the rat.

Using a sensitive radioimmunoassay we have studied the regional distribution of substance P. The level of substance P is higher in the mesencephalon, hypothalamus and preoptic area than in other regions of the brain. Substance P is found in especially high concentrations in the reticular part of the substantia nigra and the interpeduncular nucleus. It is present in large amounts in several septal, preoptic and hypothalamic nuclei as well.

Radioimmunoassay for neurotensin, a hypothalamic peptide.

A highly sensitive and specific radioimmunoassay for neurotensin has been developed which utilizes 125I-labeled neurotensin and rabbit antisera raised toward synthetic neurotensin which has been coupled specifically through its lysine side chain to several proteins. The three antisera described have different specificities but are directed primarily towards the COOH-terminal region of neurotensin which is the biologically active portion of the molecule. Two of the antisera, poly(Glu60, Lys40) (from animal no. 4) and keyhole limpet hemocyanin (from animal no. 8), cross-react fully with COOH-terminal partial sequences of neurotensin while antiserum poly(Glu60, Lys40) (from animal no. 6) requires the entire molecule for full recognition. The assay can detect less than 3 fmol of neurotensin and the dose-response curves for synthetic and native neurotensin are superimposable, irrespective of the antiserum employed. Using these assay systems, the immunoactivity in acid/acetone extracts of 45 kg of bovine hypothalami was purified to homogeneity and shown to be attributable to intact neurotensin and not to fragments of neurotensin nor to related molecules. Radioimmunoassayable neurotensin (R-NT) obtained from bovine, rat, guinea pig, and rabbit hypothalami also gave dose-response curves which paralleled that of neurotensin and the neurotensin equivalents per g of wet tissue were in the range 45 to 70 pmol/g. Measurements with the three antisera were in agreement, especially after the extracts were chromatographed on Sephadex G-25; R-NT in these hypothalamic extracts has also been shown to be destroyed by treatment with various enzymes known to cleave neurotensin.

The synthesis of neurotensin.

A tridecapeptide having the amino acid sequence, less than Glu-Leu-Tyr-Glu-Asn-Pro-Arg-Arg-Pro-Tyr-Iie-Leu-OH, (The nomenclature and symbols follow the suggestions of the IUPAC-IUB Commission on Biochemical Nomenclature (1972) J. Biol. Chem. 247, 977).) has been synthesized by the Merrifield solid-phase procedure. The synthetic scheme chosen involved synthesis of the peptide in the (Gln) form and cyclization to the less than Glu) form. After purification, the (Gln) peptide was obtained in a 7% yield and the (greater than Glu) peptide was obtained in a 35% yield. The (greater than Glu) was found to be chemically and biologically indistinguishable from the tridecapeptide, neurotensin, recently isolated from bovine hypothalami.